INTRODUCTION
WHO Grade IV astrocytoma (glioblastoma) is a uniformly fatal primary intracranial malignancy with a median survival of 14 months. 1 We conducted an earlier pilot Phase I vaccine trial in patients with high grade astrocytomas 2 and designed a replacement Phase 1 trial with optimized reagents, expanded radiographic response criteria, and new exploratory objectives.
METHODS Study Site and Patients
The study was conducted at Thomas Jefferson University and reached target accrual of 12 patients in 14 months. Criteria for enrollment included age > 18, a Karnofsky performance score of 60 or better, and no co-morbidities that would preclude elective surgical re-resection. Twelve patients were enrolled for treatment after failure from standard therapy. 1 A summary of enrolled patients, and all available pertinent data is included in Table 1 .
Study Design and Objectives
As before, the combination product consisted of autologous tumor cells removed at surgery then treated overnight with the IGF-1R AS ODN (4mg/ml) prior to being added to semi-permeable chambers and irradiated. 2 Enhancements to the vaccine product included use of an 18-mer IGF-1R AS ODN with the sequence 5'-TCCTCCGGAGC-CAGACTT-3', two frameshifts upstream from the previous sequence; and, based on data showing that the AS ODN has immunomodulatory properties, 3, 4 addition of 2 mg of exogenous antisense to the chambers (C-v). The protocol was also amended to include an eleventh control chamber containing PBS (C-p). Study objectives included assessment of safety and radiographic responses as well as exploratory objectives looking at immune function and response.
Radiological Assessments
Serial imaging assessments were performed on Philips 1.5T and 3T MRIs and GE 1.5 T MRIs. Routine anatomic MRI features were evaluated as well as physiologic measurements including dynamic susceptibility weighted (DSC) MR perfusion and 15-direction diffusion tensor imaging (DTI) were also utilized. Cytokine/chemokine levels in tumor cell supernatant were analyzed by Luminex kits as designated above. Membranes from paired vaccine and control chambers were embedded in paraffin for standard immunohistopathologic examination. Post-mortem autopsy was limited to examination of the brain and findings were compared to archival paraffin blocks of previously treated or untreated glioblastomas diagnosed at autopsy.
Immunological Assessments

Statistical Analysis
The level of statistical significance between quantitative measures in different samples was determined by a two-tailed unpaired t-test or matched pairs t-test with p < .05. Survival analysis was performed by Kaplan-Meier analysis and significance established by log rank comparisons. All statistical analysis including mixture discriminant analysis was performed with JMP v. 11 software (SAS, North Carolina).
12-myristate,13 acetate (PMA) and ionomycin as previously described.6 PBMC from glioblastoma patients and normal donors were cultured for 24 hours at 37°C and 5% CO2 in AIMV media containing 10% fetal bovine serum (Gibco). Nonadherent lymphocytes were transferred to new plates in order to eliminate non-specific effects of contaminating monocytes. Lymphocyte cultures were stimulated with phorbol 12-myristate 13-acetate (PMA, 100 ng/ml) and ionomycin (0.1 mM, both from Sigma-Aldrich) for 18 hours. BD Golgiplug™ (1:1000, Brefeldin A, BD Bioscience) was added during the last 6 hours of culture to permit cytokine accumulation.
Tumor tissue sections were assessed by immunohistochemistry or immunofluorescence, adapting the method of Emoto7, for GFAP, IGF-1R, CD163, CD14, CD3, CD4, and CD8. Immunopositive cells were counted quantitatively with Aperio or qualitatively by an experienced neuropathologist (LEK) using an ordinal scale from 0 (no staining) to 6 (strong diffuse staining) with staining intensity was obtained post-operatively on days 7, 14, 28, 42, 56, and every 3 months after vaccination. Sera and cell fractions were separated by centrifugation and cells were treated with red blood cell lysis buffer and white blood cells either quantified by flow cytometry or stored in DMSO at -80°C. Serum samples were also stored at -80°C. Flow cytometry was performed as previously described 5 using an EasyCyte 8HT (Millipore) and fluorescently-conjugated mAb specific for human CD4, CD8,CD11b, CD14, CD16, CD20, CD45, CD56, CD80, CD83, and CD 86 (all from BD Biosciences), and CD163 (R&D Systems). Post-collection analysis was performed with FlowJo software (Tree Star Inc, Ashland, OR). Serum cytokine factors were quantified using Luminex bead arrays (human cytokine/chemokine panels I, II, and III from Millipore and HCMBMAG/ MILLIPLEX Mag Cancer multiplex assay (emdmillipore.com). This included 6 serum markers for glioma related to stem cell function including DKK-1, NSE, Osteonectin, Periostin, YKL-40, and TWEAK. T-cell stimulation was performed with phorbol Actual CD4 and CD8 T cell counts as well as DC counts were significantly higher in the longer cohort compared to the short cohort. There was a significant correlation between CD4 and DC cells and between CD4 and CXCL12 only in the longer cohort. Coordinated changes between circulating levels of T cells, monocytes, and pro-inflammatory chemokines/cytokines after vaccination were seen in three of four longer cohort subjects.
As a distinguishing feature differentiating the cohorts, peripheral blood cells from the longer survival subjects manifested significantly higher Th-1 cytokine production including IFN-g after stimulation with PMA and ionomycin from PBMC obtained on day 14.
Levels of circulating lymphocytes were significantly decreased (p<0.0001) in all GBM patients when compared to normal subject samples ( Figure 1A , left panel) and the medians of both patient populations fell outside of the normal range ( Figure  1A , gray lines). Patients in this same cohort exhibited significantly higher levels of monocytes ( Figure 1A , right panel, p<0.05), but the medians of these cell populations fell within normal range.
The mere presence of a given cell subset is not enough to ensure proper immune function. The cell must also be able to respond to stimuli and produce at the primary tumor site and slower progression. Examples of anatomic responses in both cohorts is included noted in Figure 2A&B . Physiologic MRI measurements augmented these anatomic observations for both cohorts is featured in Figure 2C&D . Sequential DSC MR perfusion was performed in 7 patients, including 3 longer-term survivors (TJ03, TJ06, and TJ09) who had a paradoxical increase in rCBV while improving clinically; however, this effect was transient and there was a more sustained decrease in rCBV. Sequential 15 directions DTI data included two long-term survivors (TJ03 and TJ06) who showed ADC values increasing in the affected hemisphere, reflecting loss of tumor cellularity associated with disease regression.
Immunologic Response Assessments after Vaccination by Survival Cohort
Levels of 24 of the 78 cytokines/chemokines assessed were significantly higher in serum from the longer survival cohort compared to the short cohort. A spike in serum CCL2 occurred after surgery but was absent at re-operation in two patients. CCL2 levels remained significantly higher throughout the post-operative period in the short survival cohort. These postoperative spikes were highly correlated with TNF-a spikes. (data not shown).
RESULTS
Safety Assessment and Clinical Course
Only one SAE was related to the protocol (femoral vein thrombosis after leukopheresis). Nine patients succumbed to tumor progression while three patients died from other causes. Five autopsies were performed.
Median overall survival from initial diagnosis was 91.4 weeks which compared favorably to other recurrent glioma immunotherapy trials. [8] [9] [10] [11] [12] [13] Two significantly different protocol survival cohorts of 48.2 and 10 weeks were identified as longer and short survival cohorts, respectively ( Figure 1A&B ). Excluding one outlier (TJ03), we documented a significant correlation between protocol survival and degree of lymphopenia at enrollment ( Figure 1C) . Comparison of CBC values at initial diagnosis and at protocol enrollment indicated that the mean lymphocyte count had dropped significantly (65%) after standard therapy (N=8, p = .012, paired t-test).
Radiographic Responses
Routine MRI features were assessed as previously described. 2 In the longer survivors we noted diminished size of enhancement and FLAIR envelope A. Overall survival of patients in trial; B. protocol survival with two survival cohorts; Nine patients died of disease progression while one died of intracerebral hemorrhage and two of sepsis. Overall protocol survival was 48.2 weeks and 9.2 weeks, respectively for longer (N = 4) and short (N = 8) survival cohorts (log-rank = .014). C. Excluding one outlier and three non-disease-related deaths linear regression revealed high correlation between protocol survival and lymphocyte count at enrollment (R2 = .8, p = .0028). Reanalyzing these data focusing on single parameters based on the functional immune capacity confirmed the highly significant differences identified by recursive partitioning (Supplementary Figure 1) . Patients with higher immune function possessed 3-fold higher levels of lymphocytes (p<0.0001) and half as many monocytes (p<0.005) when compared to the lower functioning group (Supplementary Figure 1 ). In addition to higher levels of lymphocytes, the T cells from patients with higher immune function produced twice as much IFN-g following stimulation patients with primary and recurrent GBM produced significantly less IFN-g when compared to normal controls (p< 0.01), but there was no difference between GBM patient cohorts ( Figure 1B , right panel).
Moreover, while a difference in the quantity of IFN-g produced by the T cells was observed, there was no difference in the frequency of IFN-g+ T cells between these two cohorts (data not shown). In order to assess the relationship between lymphocyte numbers and immune functional capacity, we performed linear regression analyses. Lower levels of circulating lymphocytes are associated with a statistically significant (R2=0.508, p=0.0093) decrease in IFN-g production following PMA/ionomycin stimulation appropriate immune modulators. T-helper type 1 immunity is considered to be the appropriate anti-tumor immune response. Cultures of nonadherent lymphocytes were stimulated nonspecifically with phorbol 12-myristate 13-acetate (PMA) and ionomycin overnight in order to stimulate the production of IFN-g, the prototypical Th1 cytokine which was detected by intracellular cytokine flow cytometry. Viable, CD3+ T cell-specific gates were established ( Figure 1B Evolution of resistance to treatments in gliomas has now been associated with activation of the IGF-1R signaling axis and IGF-1R inhibition through a small molecule inhibitor overcomes this resistance with improved outcomes. 23 We are currently exploring the impact of the IGF-1 bioregulatory system in recurrent gliomas and the impact of the IGF-1R AS ODN in this vaccination paradigm.
Differences in the radiographic observations between the longer and short survival patient cohorts provide further support for the concept that the vaccination paradigm may have an impact on the glioma TME. Higher rCBV values are typically associated with tumor progression, 24 and MR perfusion had only transient increases in the longer cohort, a finding not previously described. ADC measurements differentiated tumor progression (lower values) from what we interpreted as cell loss (higher values). 25 In summary, we have established the safety profile of an improved combination glioma vaccine product and have documented alterations in immune parameters associated with clinical and radiographic improvements. Despite immune compromise, we documented favorable immune responses associated with tumor regression and longer survival after treatment. To be most effective, however, a replacement trial should include screens for immune compromise and means by which immune function could be restored prior to vaccination.
Study Oversight
The physician sponsor (DWA) was primarily responsible for the design and funding of the study. All authors participated in the conduct of the study, analysis of the data and the reporting of the results. After IRB approval, this study was overseen by an independent data safety and monitoring board appointed by the Sidney Kimmel Cancer Center at Thomas Jefferson University.
DWA and DCH have financial interests in the Imvax Corporation related to this work.
higher levels of tumor-specific antibody isotypes and cytokines/chemokines commonly associated with Th1 immunity including IgG1, IgG3, IL12, CXCL10, CXCL12, CCL7, CCL19, and CCL21 not seen in the short cohort.
The short survival cohort had longer overall survival perhaps in part due to MGMT methylation and better responses to temozolamide in three patients. However the treatment-induced lymphopenia and the lower CD4:CD8 ratio could perhaps also be ascribed to temozolamide. Also, elevated serum CCL2 levels found in the short cohort have been associated with the mesenchymal gene expression profile 19 and a poor prognosis 20 in glioma patients.
Cytokine production is a hallmark feature of immune function in lymphocytes. We used phorbol ester-mediated, non-specific stimulation of patient lymphocytes in order to stimulate maximal cytokine output as a surrogate indicator of immune function. IFN-g is the classical Th1 cytokine and the logical choice for assessing immune fitness of T lymphocytes in our GBM patients. The amount of IFN-g production by T cells following overnight stimulation was approximately half the amount produced by normal donor cells treated similarly. IFN-g production and lymphocyte counts were strongly associated and predictively identified patients with different levels of immune fitness that fell into either the longer or short survival cohort. Lymphocytes from patients with higher functional immune capacity were more frequent and produced higher levels of IFN-g that approached levels to those produced by normal lymphocytes stimulated under similar conditions. In contrast, T cells from trial patients in the lower immune function cohort were less in number (50%) and unable to respond to PMA stimulation.
The implanted chambers have inherent adjuvanticity. We have confirmed that the antisense sequence, its CpG motif, and the direct mixture with glioma cells in situ effectively initiate anti-tumor immunity 3 also noted by others. 21, 22 The CpG motif specifically interacts with TLR94 causing plasmacytoid DC activation, measured by CD80 and CD86 expression. 5 The elevated CD4:CD8 ratio after vaccination in the longer survival cohort could reflect local TLR9 DC activation and CD4 T cell stimulation.
with PMA/ionomycin (Supplementary Figure 1, p<0.01) . Subsequent analyses will focus on patients with higher/lower functional immune capacity. Analysis of hospital-acquired blood cell counts fail to take in to consideration immune cell subsets. We performed flow cytometry phenotyping in order to further characterize the white blood cells. Frequencies of CD20+ B cells were significantly decreased in those patients with lower cohort (p<0.005) and fell outside of the normal average (Figure 2 ). CD4+ T cells in both cohorts were significantly lower than the normal average, while CD14+ monocytes were significantly increased compared to normal averages ( Figure 2 ) in both partitioned cohorts. CD8+ T cells in both cohorts were similar to normal averages ( Figure 2 ). There was no difference between the lower and higher cohorts with respect to CD4+ or CD8+ T cell, or CD14+ monocyte frequencies (Figure 2 ).
DISCUSSION
Like its predecessor, the revised autologous cell/chamber-based GBM vaccination trial did not raise any significant safety concerns. We recognized, however, that an immunotherapy trial for recurrent GBM faces incumbent challenges. Patients emerging from standard therapy for GBM often have severe leukopenia, 14 which was also documented in the current trial. It was therefore not surprising that we could not document T cell infiltrates in the TME after treatment. Surgery itself enhances host immune mechanisms favoring tumor growth through the attraction of M2 macrophages to the tumor environment postoperatively 15, 16 suggested by the CCL2 serum spike provoked by craniotomy. Other than this post-operative serum spike, the highest levels of CCL2 expression were found in the tumor supernatants during vaccine preparation supporting well-documented observations that CCL2 is produced from cells in the TME. 17, 18 The lack of a CCL2 peak after re-vaccination in two patients suggested loss of these cells after the first vaccination.
We identified two significantly different survival cohorts with different responses to this vaccine paradigm allowing us to explore the nature of potentially therapeutic immune mechanisms. Serum from the longer cohort subjects contained
